Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05445908
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
- NCT05445908 ↗
- Completed
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on NCT05445908 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05445908 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic Therapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Triple-negative Breast Cancer and HR+/HER2- BC
- Interventions
- SKB264; KL-A167
- Arms
- SKB264+KL-A167（Part1，TNBC） · Experimental
- SKB264（Part2，TNBC） · Experimental
- SKB264+KL-A167（Part2，TNBC） · Experimental
- SKB264（Part3，HR+/HER2- BC） · Experimental
- SKB264+KL-A167（Part3，HR+/HER2- BC） · Experimental
- Enrollment
- 184
- Primary outcomes
- Incidence and severity of adverse events (AEs)
- Objective Response Rate (ORR)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Aug 17, 2022
- Primary completion
- Jul 31, 2026
- Results posted
- No
- Registry record
- NCT05445908 · updated Aug 28, 2026